Bristol-Myers: Eliquis reduces stroke risk.
(CercleFinance.com) - Anticoagulant Eliquis has been associated with a reduced risk of stroke and embolism, as well as lower rates of major bleeding compared to warfarin, Bristol-Myers Squibb and Pfizer said on Monday.
The drugmakers said this real-world data pooled from four large US insurance claims databases will be presented at ESC Congress 2017 in Barcelona.
"Stroke events continue to be a major concern for patients with non-valvular atrial fibrillation (NVAF) as well as their healthcare providers, and these findings supplement Eliquis clinical trial data," said Bristol-Myers Squibb.
Eliquis has been jointly developed by Pfizer and Bristol-Myers Squibb.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The drugmakers said this real-world data pooled from four large US insurance claims databases will be presented at ESC Congress 2017 in Barcelona.
"Stroke events continue to be a major concern for patients with non-valvular atrial fibrillation (NVAF) as well as their healthcare providers, and these findings supplement Eliquis clinical trial data," said Bristol-Myers Squibb.
Eliquis has been jointly developed by Pfizer and Bristol-Myers Squibb.
Copyright (c) 2017 CercleFinance.com. All rights reserved.